• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Fisher & Paykel come out on top in German patent spat with ResMed

Fisher & Paykel come out on top in German patent spat with ResMed

December 1, 2016 By Fink Densford

ResMed, Fisher & PaykelFisher & Paykel Healthcare (NZE:FPH) said last Friday that a German court overturned preliminary injunctions granted to ResMed (NYSE:RMD) in a patent infringement case filed in August.

With the overturned injunction, Fisher & Paykel said it has resumed sales of its Simplus full face mask, Eson nasal mask and Eson 2, which San Diego-based ResMed claimed infringed on its patents.

Fisher & Paykel shares have jumped on the news, rising 6.2% to close at $8.72. The company had previously lost more than 21% since ResMed filed legal action on August 18.

“We are pleased with the outcome of the first two hearings in these patent dispute proceedings and we remain confident in regards to future proceedings,” Fisher & Paykel CEO Lewis Gradon said in a press release.

Fisher & Paykel initiated the hostilities with an August 15 lawsuit in a California federal court, alleging that ResMed’s AirSense 10 and AirCurve 10 flow generators, ClimateLineAir heated air tubing and Swift mask line infringe 11 of its patents. The Auckland, N.Z.-based company moved to withdraw that suit the next day, but reserved the right to sue again, according to documents filed with the U.S. District Court for Central California.

On August 18, ResMed announced a responding barrage, with actions filed in another California federal court, plus Germany, New Zealand and the ITC. The lawsuit filed in the U.S. District Court for Southern California alleges that Fisher & Paykel’s Simplus full face mask, Eson nasal mask and Eson 2 nasal mask infringe 4 of ResMed’s patents and asks the court to invalidate its Down Under rival’s patents, find that it’s not infringing, or both.

ResMed sought an injunction from the ITC banning Fisher & Paykel from importing the allegedly infringing devices and claimed a win in Germany. The Munich District Court granted ResMed’s bid for a pair of preliminary injunctions stopping the sale of the Simplus, Eson and Eson 2 devices. In New Zealand the company is seekingto halt the manufacture and exportation of the devices, ResMed said.

Material from Reuters was used in this report.

Filed Under: Legal News, Respiratory Tagged With: Fisher & Paykel Healthcare, ResMed Inc.

More recent news

  • Data backs DermaSensor skin cancer detection device
  • GE HealthCare expands digital imaging portfolio with enhanced MIM Encore software
  • Accelus wins FDA clearance for MRI compatibility of FlareHawk spinal implants
  • Presidio wins FDA IDE for ultra-low frequency neuromod, hires new CFO
  • Epiminder study backs implantable EEG tech

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy